Search

Your search keyword '"Ghezzi, Angelo"' showing total 694 results

Search Constraints

Start Over You searched for: Author "Ghezzi, Angelo" Remove constraint Author: "Ghezzi, Angelo"
694 results on '"Ghezzi, Angelo"'

Search Results

4. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study

5. Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset

7. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

8. International Pediatric MS Study Group Clinical Trials Summit

11. The Italian multiple sclerosis register

17. Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis:A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment

20. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

21. A Comprehensive Review on Copemyl®

25. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks

26. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks

30. Correction to: The Italian multiple sclerosis register

32. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years

33. Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study

35. Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEQ-IT)

36. Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)

37. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

38. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients

40. sj-docx-1-mso-10.1177_20552173211059048 - Supplemental material for Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)

41. sj-docx-2-mso-10.1177_20552173211059048 - Supplemental material for Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)

42. The introduction of new medications in pediatric multiple sclerosis:Open issues and challenges

43. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

46. Brain macro- and microscopic damage in patients with paediatric MS

47. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs

49. Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)

50. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience

Catalog

Books, media, physical & digital resources